Takeda works on drug to treat COVID complications
Universities collaborate on medicine that might prevent blood vessel inflammation
Researchers at Takeda Pharmaceutical and two Japanese universities hope to bring their drug to market in a few years.
TOKYO -- Takeda Pharmaceutical and two Japanese universities are developing a drug to treat the clogging and inflammation of blood vessels, complications of COVID-19.
The drug uses a mechanism different from those of existing coronavirus drugs, and the developers report that it will likely help prevent the aggravation of COVID-19 symptoms.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapterFind out more
Free access for everyone - Sep. 30